Jeff Kindler

CEO, Centrexion Therapeutics · 1 appearance on the record.

computed by AI from the episodes · how this works → · full disclaimer →

executiveinvestorLinkedIn ↗centrexion.com ↗Wikipedia ↗

Jeff Kindler served as Chairman and CEO of Pfizer from 2006 to 2010, where he orchestrated the $68 billion acquisition of Wyeth. He currently leads non-opioid pain therapy biotech Centrexion Therapeutics as CEO and advises healthcare investment initiatives.

7statements → 4claims → 1claims resolved → 3.57/5average certainty → 2.29/5average debate potential →

1 supported 0 partly supported 0 contradicted 3 not checkable as stated how the 4 claims stand · each chip opens the sources

3 predictions · 1 assertion · 1 insight · 2 disclosures · every statement was checked. The predictions and assertion are the 4 claims: statements the public record can support or contradict. 1 is resolved, and 3 name no date, number or outcome precise enough to check. Everything else (opinions, insights, what ifs, disclosures) can never be settled by the record, so it carries no assessment.

The record, in short

What the tape says about how Jeff argues and how the claims held up. Everything they said, and everything said about them, is in the tabs below.

Their most notable supported claim

Assertion Supported

Kindler: FDA only recently permitted direct electronic clinical data entry

“It was only relatively recently that the FDA Allowed clinical data to be entered directly into computers as opposed to put on paper because there was a reluctance to trust the quality and integrity of that data, which I think we would all agree is kind of sill…”

Jeff Kindler Jan 2, 2019 ▶ 23:13 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

How they sound: speaking style how? →

252 words/min while actually speaking · 35.2 um and uh per 1k words

No argument clarity score for Jeff Kindler: no usable question→answer exchanges on raw tape (a fair score needs 8+). We do not score a sample that small. Roundtable and news formats yield far fewer direct exchanges than interviews.

Measured by listening to the audio itself: 2,273 words across 1 episode of raw-level tape, transcribed verbatim with every um and uh kept, each one attributed only where the alignment onto our timed stream is unambiguous. These are measurements of speaking style. We do not rank them: across this corpus, fluency and argument quality are nearly uncorrelated (ρ≈0.2), and smooth talking does not signal clear thinking. How it's measured →

What they said7 Episodes1

Everything Jeff Kindler said on the a16z Podcast that made the record, most notable first. Filter by type, assessment or year in the ledger →

Prediction Not checkable as stated

Kindler: Pharma will virtualize and outsource all functions except commercialization

“And in my opinion, the thing they're really good at that I find it hard to imagine being disrupted in the very near future is that translational stage from late stage assets to initial commercialization, figuring out what the market wants. And again, By analog…”

Jeff Kindler Jan 2, 2019 ▶ 19:28 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

Prediction Not checkable as stated

Kindler: Future pharma innovation will originate outside big pharma incumbents

“I imagine a lot of this Innovation will come outside of big pharma, but the big pharma's that succeed will be the ones that get it.”

Jeff Kindler Jan 2, 2019 ▶ 27:19 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

Insight

Former Pfizer CEO: Pharma is unbundling into an outsourced model

“I think pharma is in the process of making a similar shift. For many years, until even relatively recently, they were one of the full, one of the few fully integrated industries in the sense that they did everything in house from discovery through the end of a…”

Jeff Kindler Jan 2, 2019 ▶ 1:53 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

Prediction Not checkable as stated

Kindler: Payers will force pharma to adopt widespread data sharing

“The payers probably have more and better real-world data than the pharma companies do, and one of the reasons that the pharma companies will eventually, in my opinion, have to do data sharing, as Andrew suggests, is that the payers are going to aggregate their…”

Jeff Kindler Jan 2, 2019 ▶ 15:33 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

Disclosure

Kindler backs a 10-person virtual pharma company generating $150M EBITDA

“So for example, I'm an investor in a specialty pharma company that has about a hundred and fifty million dollars of EBITDA and it's got 10 employees because it never built that infrastructure because like my movie analogy, it puts together each deal as it need…”

Jeff Kindler Jan 2, 2019 ▶ 17:39 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

Disclosure

Former Pfizer CEO teases stealth startup automating pharmaceutical animal models

“So I'm involved with a company that's still in stealth, but you'll hear a lot about it very soon. And what it's doing is addressing a sort of small corner, not much spoken about part of the pharmaceutical industry, which is animal models.”

Jeff Kindler Jan 2, 2019 ▶ 6:15 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

Assertion Supported

Kindler: FDA only recently permitted direct electronic clinical data entry

Jeff Kindler Jan 2, 2019 ▶ 23:13 a16z Podcast | Move Fast But Don't Break Things (When It Comes to Computational Biology)

Appearances (1)

Episode	Date	Speaking time
a16z Podcast \| Move Fast But Don't Break Things (When It Comes to Computational Biology)	Jan 2, 2019	10m

Jeff Kindler

The record, in short

Their most notable supported claim

How they sound: speaking style how? →

Appearances (1)

Turn any episode into a week of clips.